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Abstract: Since the pivotal discovery by Harrington and coworkers in 1951 it is well 
recognized that a serum factor, subsequently localized to the immunoglobulin fraction, 
is involved in the pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP). 
Over the years, much effort was devoted to the development of techniques for the 
detection of this platelet antibody. Assays measuring the total platelet 
immunoglobulin content were shown to be neither specific nor sensitive enough. In 
the early 1980: s it became evident that certain platelet membrane glycoproteins (GPs) 
were targeted by autoantibodies, alloantibodies and carried blood group ABO antigens. 
As a consequence thereof refined and antigen-specific assays were developed. 
Currently, few data are available regarding the epitopes on the GPs acting as 
autoantigens. Nevertheless, it has been hypothesized that the autoantibodies in 
chronic ITP are clonally derived. The purpose of the present study was to: (a) evaluate 
different techniques, suitable for the routine laboratory, for detection of platelet 
antibodies in patients with ITP, (b) explore the hypothesis of clonally derived 
autoantibodies in ITP, and (c) characterize blood group A antigen expressing platelet 
GPs. Blood and serum samples were obtained from patients with an unequivocal 
diagnosis of chronic ITP. Employing whole platelet based assays (whole platelet 
ELISA and flow cytometry) platelet antibodies were detected in approximately 35% 
of the ITP patients, and the platelet antibodies were most frequently found to belong 
to the IgG immunoglobulin class. Using an antigen specific assay, the modified 
antigen capture ELISA (MACE), antibodies specific for GPIIb/IIIa and/or GPIb/IX 
were recorded in about one third of the ITP patients. However, there was a 
discrepancy as to results between the assays. Due to low sensitivity none of the assays 
can be recommended for routine clinical use in the differential diagnosis of 
thrombocytopenias. The results obtained support the hypothesis of clonally derived 
autoantibodies in chronic ITP. Thus, first, we found that these autoantibodies, in the 
majority of patients, were light chain restricted; second, IgG-F(ab')2 fragments 
prepared from two prototype ITP patients with known anti-GPIIb/IIIa were each able 
to block the binding of serum IgG to GPIIb/IIIa in at least 50% of other ITP patients, 
favoring a homogeneous autoepitope repertoire. However, an expanded clonal B-cell 
population could not be detected by using flow cytometric "clonal excess" analysis or 
PCR-analysis of Ig-gene rearrangements (CDR3). Apart from the previously reported 
blood group A-antigen expressing platelet GPs, i.e. GPIb, GPIIa, GPIIb, GPIIIa and 
PECAM, we observed that an anti-A antibody immunoblotted and immunoprecipitated 
some other uncharacterized GPs which had a molecular weight of 70-90 kD. These 
latter platelet proteins were characterized by us as platelet GPIV and GPV. 
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"Morbus maculosus haemorrhagicus" 
An adult girl, without manifest cause, was attacked 
recently, towards the period of her menses, with a 
sudden severe hemorrhage from the nose, with bright 
but foul blood escaping together with a bloody 
vomiting of a very thick extremely black blood. 
Immediately there appeared about the neck and on 
the arms, spots partly black, partly violaceous or 
purple, such as are often seen in malignant 
smallpox...; moreover the number of the spots 
increasing and surrounding completely both of the 
eyes, the back of the nose and the skin around the 
mouth and chin, with a livid black color, like marked 
from bruises 
Opera Medica, Paul Gottlieb Werlhof, 1776 
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INTRODUCTION 
Clinical features 
In his book Opera Medica, published in 1776, Paul Gottlieb Werlhof devoted a chapter 
to "Morbus maculosus haemorrhagicus", which he first described forty years earlier 
(Werlhof, 1776). A profound diminution in platelet count in Werlhof's disease was first 
recognized by Krauss (1883), and since the 1950s, it has been recognized that platelets 
can be destroyed by immunologic processes. Antiplatelet antibodies can target at 
alloantigens, autoantigens, and drug-induced neoantigens (Aster, 1989); high titer 
ABO antibodies can also cause refractoriness to ABO incompatible platelet 
transfusions (Aster, 1965; Duquesnoy et al, 1979; Skogen et al, 1988). Immune 
mechanisms involving the platelet-specific alloantigens are seen in two distinct 
clinical entities, neonatal alloimmune thrombocytopenic purpura (NATP) and 
posttransfusion purpura (PTP). In NATP destruction of the fetal platelets is caused 
by transplacental^ acquired maternal antibodies directed against platelet-specific 
alloantigens inherited from the father and lacking in the mother (Aster, 1989); an 
incompatibility in the diallelic alloantigen HPA-1 (P1A1/A2) 0r HPA-5 (Br^) is most 
commonly seen (Mueller-Eckhardt et al, 1989). PTP, also caused by platelet-specific 
alloantibodies, occurs about a week after a red cell or platelet transfusion (Aster, 
1989; Taaning & Svejgaard, 1994). This disease is typically seen in an elderly 
multiparous and HPA-la-negative (PlA1-negative) woman, who previously has been 
transfused with blood products. However, these two conditions are rare and idiopathic 
thrombocytopenic purpura (ITP), caused by autoantibodies directed against certain 
platelet antigens, is the most common entity of the immune thrombocytopenias. ITP 
is an acquired disorder and can affect both children and adults. However, the clinical 
syndromes of ITP are distinct between children and adults. Childhood ITP 
characteristically is acute in onset, occurs within one or two weeks of a n infection 
usually of v iral origin, and resolves spontaneously within six months - acute ITP. 
Adult ITP typically has an insidious onset and rarely resolves spontaneously - chronic 
ITP (George et al, 1995). 
Chronic ITP is a diagnosis made by exclusion, and the following diagnostic criteria are 
frequently applied: (1) thrombocytopenia (platelet count <100 x 10 9/1) for at least six 
6 
months, (2) no known underlying disease, e.g. lymphomas, systemic lupus 
erythematosus, or HIV-infection, (3) normal or increased number of megakaryocytes 
in a bone marrow biopsy, and (4) a normal spleen size (Karpatkin, 1980). The 
incidence of chronic ITP among adults is approximately 6/100,000, women are affected 
more frequently than men (3:1), and 70 percent of the women are less than 40 years 
old (George et al, 1994; George et al, 1995). The clinical picture can sometimes be 
dramatic with severe bleedings from skin and mucous membranes, and the platelet 
count is not corrected by platelet transfusions. Frequently, corticosteroid treatment 
will raise the platelet count to normal values within 1-2 weeks; deaths from severe 
hemorrhages are rare but may occur especially in elderly patients (Pizzuto & Ambriz, 
1984; Cortelazzo et al, 1991). Complete and sustained remissions (CR) are, however, 
only obtained in 30% of patients treated with corticosteroids (for review see: George 
et al, 1995). Other treatment modalities, i.e. high dose intravenous immunoglobulins 
(IVIg) and cytostatic drugs, have been shown to be effective in chronic ITP (for review 
see: George et al, 1995). Following splenectomy, complete and sustained remissions 
will be obtained in approximately 65% of the patients with chronic ITP; over one third 
of the splenectomized patients do not obtain a complete remission, and many of them 
will require continuous medical treatment (George et al, 1994; George et al, 1995). 
Pathophysiology 
In the 1950s, the term idiopathic thrombocytopenic purpura referred to a clinical 
disorder of unknown etiology associated with thrombocytopenia and purpura. It was 
reported that mothers with ITP often gave birth to children who developed transient 
thrombocytopenia, suggesting the transfer of a humoral factor (Robson & Davidsson, 
1950; Epstein et al, 1950). Harrington and coworkers reported in 1951 direct evidence 
for the existence of a serum factor responsible for the thrombocytopenia in ITP; when 
plasma from patients with ITP was given intravenously to healthy volunteers or 
patients with inoperable malignant neoplasms, a marked and transient 
thrombocytopenia was seen in more than half of th e recipients (Harrington et al, 
1951). The factor responsible for the platelet destruction was subsequently shown to 
carry many characteristics of an antibody, i.e. it was present in the Ig-fraction of 
serum, it was absorbed from serum by normal platelets, and the degree of p latelet 
destruction was proportional to the amount of serum infused (Shulman et al, 1965). 
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Increasing doses of ITP plasma transfused to healthy recipients aggravated the 
thrombocytopenia; when splenectomized recipients were transfused much higher doses 
were required, suggesting that splenic removal, rather than vascular destruction was 
of importance (Shulman et al, 1965). Also, when ITP plasma was given during steroid 
protection, a less pronounced thrombocytopenia was elicited. 
The spleen is considered to be a major site of antiplatelet antibody production in 
chronic ITP. It has been reported that the spleen in ITP displays lymphoid 
hyperplasia and alterations in the microcirculation (Tavasolli & McMillan, 1975; 
Schmidt et al, 1991). In chronic ITP platelet kinetic studies using 61Cr- or lllIn-
labelled platelets have, apart from a profoundly shortened platelet mean life span, 
demonstrated that the spleen is the major site for platelet destruction (Aster & Keene, 
1969; Harker & Finch, 1969; Branehög et al, 1974; Ballem et al, 1987; Siegel et al, 
1989). The platelet production rate is most commonly elevated, as reflected by an 
increased bone marrow megakaryocyte number and size (Branehög et al, 1975). 
However, it has been reported that the platelet production rate may be reduced in 
some cases of ITP, possibly due to the effect of platelet autoantibodies on the 
megakaryocytes (McMillan et al, 1978; Hoffman et al, 1985; Stoll et al, 1985; Heyns 
et al, 1986; Ballem et al, 1987) 
Antiplatelet antibodies 
Early assays for platelet antibody detection were designed to measure the effect of 
patient plasma on the function of normal platelets, e.g. induction of platelet 
aggregation, secretion and lysis. However, these tests were insensitive to the 
abnormalities specific for ITP (Jackson et al, 1963; Aster & Enright, 1969; Hirschman 
& Shulman, 1973). Studies aimed at quantification of platelet associated IgG (PAIgG) 
opened a new era in the investigation of immune thrombocytopenias (McMillan et al, 
1971). High PAIgG values were found in patients with ITP, and it was assumed that 
all platelet IgG was located on the platelet surface and constituted antiplatelet 
antibody (Dixon et al, 1975; Luiken et al, 1977). Further studies, however, showed 
that normal platelets contain two distinct pools of IgG, one surface located and one 
intracellular. The surface oriented pool has been estimated to contain about 100 
molecules of IgG. Intracellular^, however, approximately 20,000 IgG molecules are 
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stored in the a-granules (George, 1989; George, 1990). The original techniques used 
for the detection of PAIgG measured the total platelet IgG, i.e. the a-granule IgG-
content was included, and the data obtained were inaccurately assumed to be a 
measure of platelet surface IgG (Kelton et al, 1979; Kelton et al, 1980; Tsubakio et al, 
1981). 
PAIgG 
Total platelet IgG is increased in ITP, and is inversely related to the platelet count, 
i.e. the highest values are seen in the most severe thrombocytopenias (Kelton et al, 
1982; George, 1990). On the other hand, also patients with non-immune 
thrombocytopenias demonstrated elevated levels of t otal platelet IgG (Kelton et al, 
1982; Kelton et al, 1989). Indeed, it has been shown that nearly all thrombocytopenic 
platelets contain more IgG, IgA, IgM and albumin than normal platelets, and that the 
increased PAIgG might be related to an increased platelet volume and enhanced 
thrombopoietic stimulation (Dixon et al, 1975; Luiken et al, 1977; Zeigler et al, 1978; 
Hegde et al, 1981; Nel et al, 1983; George & Saucerman, 1988; Hattori et al, 1992). 
Such platelets are larger and contain more IgG when the thrombocytopenia is severe; 
these variables return to normal values when the platelet count is normalized. This 
is true for all patients with an increased platelet production, but is not seen in 
patients with thrombocytopenia caused by bone marrow failure (George, 1990). An 
increased PAIgG is also observed in disorders with elevated plasma IgG 
concentrations, e.g. multiple myeloma, liver diseases, and chronic 
inflammatory/infectious diseases; in these conditions the increased PAIgG mainly 
reflects an increased plasma IgG (McGrath et al, 1979; Landolfi et al, 1980; Barrison 
et al, 1981; George & Saucerman, 1988), and not an enhanced platelet turnover. 
Platelet surface IgG 
Platelet surface IgG was measured directly by the binding of a 125I-labelled monoclonal 
antibody to the Fc-region of al l subclasses of IgG (LoBuglio et al, 1983; Court et al, 
1987; George, 1991) or by 125I-labelled staphylococcal protein A (Shaw et al, 1984). By 
using these techniques it has been clearly shown that even normal platelets have 
surface oriented IgG, but the origin of this IgG is unknown (Court et al, 1987). In ITP, 
platelet surface IgG is always increased and the level is higher in acute non-treated 
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patients than in patients with chronic refractory ITP; the levels can also fluctuate in 
the individual patient during the course of the disease (Cines & Schreiber 1979; 
Court et al, 1987; George, 1990). In many patients with thrombocytopenia of n on­
immune etiology or due to bone marrow failure, platelet surface IgG is also increased 
(Shaw et al, 1984; Court et al, 1987; George, 1988; Kelton et al, 1989; George, 1990; 
George, 1991). 
Antibodies to surface glycoproteins. 
In 1982 van Leeuwen and collaborators provided the first evidence for autoantibody 
binding to certain platelet glycoproteins in chronic ITP (van Leeuwen et al, 1982). 
They used the platelet suspension immunofluorescence test (PSIFT) and found that 
platelet eluted antibodies bound to normal but not to thrombasthenic platelets in 32 
out of 42 patients with chronic ITP. Thrombasthenic platelets are known to lack the 
glycoprotein (GP) Ilb/IIIa complex, and the authors suggested that ITP patients had 
autoantibodies targeting one of these glycoproteins (van Leeuwen et al, 1982). Woods 
et al (1984a; 1984b), using a microtiter well assay, demonstrated the binding of 
autoantibodies from ITP patients to the GPIIb/IIIa or GPIb/IX complexes. Their 
observations were further confirmed by immunoprecipitation. In addition, Beardsley 
et al (1984), using an immunoblot assay, demonstrated autoantibody binding to 
GPIIIa in plasma of ch ildren with chronic ITP. Two novel assays were reported in 
1987, the immunobead assay (McMillan et al, 1987) and the monoclonal antibody 
specific immobilization of platelet antigens (MAIPA) assay (Kiefel et al, 1987). These 
two assays have the advantage of allowing the measurement of both platelet-
associated and plasma autoantibodies against platelet GPs, while the prior assays 
were limited to the detection of only plasma autoantibodies. Using these techniques, 
GPIIb/IIIa and GPIb/IX have been the most frequently encountered autoantigens in 
chronic ITP (McMillan et al, 1987; Kiefel et al, 1991; Fujisawa et al, 1993a). However, 
autoantibodies binding to GPIa/IIa and GPIV have been described (He et al, 1994). A 
direct assay of platelet-associated glycoprotein-specific autoantibodies are considered 
more frequently to yield a positive result in ITP compared to assays of plasma 
antibodies (McMillan et al, 1987; Kokawa et al, 1993). Moreover, the titers of the 
glycoprotein-specific autoantibodies have been reported to vary inversely with the 
degree of th rombocytopenia during the course of th e disease (Berchtold & Wenger, 
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1993). Also, the antibody titer was shown to decrease in association with improved 
platelet counts following treatment with corticosteroids, splenectomy, and 
cyclophosphamide; no change in antibody titer was seen with vincristine and danazol 
therapy, despite an increase in platelet count (Fujisawa et al, 1993b). 
Glycoprotein autoantigenic repertoire 
A few previous studies have addressed the repertoire of autoantigenic epitopes on 
GPIIb/IIIa by analyzing the competitive binding between human autoantibodies and 
murine monoclonal antibodies (MoAbs) (Varon & Karpatkin, 1983; Tsubakio et al, 
1987; Fujisawa et al, 1990). Also, enzyme cleaved GPIIb or Ilia fragments, and 
synthetic peptides corresponding to different sequences of GPIIIa have been used to 
localize epitopes on the respective glycoprotein (Tomiyama et al, 1989; Fujisawa et al, 
1991; Kekomaki et al, 1991; De Souza et al, 1992; Fujisawa et al, 1992). Moreover, GP 
specific human MoAbs have been developed as important tools in the search for GP 
autoepitope8 in chronic ITP; until now only a few cryptic epitopes on GPIIb/IIIa have 
been recognized using such antibodies (Nugent, 1987; Kunicki et al, 1990; Kunicki et 
al, 1991). Despite the fact that a few investigators (Tomiyama et al, 1989; Fujisawa 
et al, 1991; Kekomaki et al, 1991; De Souza et al, 1992; Fujisawa et al, 1992) have 
been successful in localizing certain autoantigenic epitopes to regions of G PIIb or 
GPIIIa, the blocking experiments using murine MoAbs have provided contradictory 
data regarding the homogeneity of the GPIIb/IIIa autoantigenic repertoire (Varon & 
Karpatkin, 1983; Tsubakio et al, 1987; Fujisawa et al, 1990). Kekomaki et al (1991) 
found that a 33 kD chymotryptic core fragment of GPIIIa was a frequent target for 
autoantibodies in chronic ITP. Moreover, in a study by Nugent and coworkers (1989) 
it was shown that the repertoire of idiotypes expressed by human antibodies specific 
for platelet membrane glycoproteins in chronic ITP could be narrowly defined, 
mimicking a clonal restriction. Further support for the hypothesis of clonal 
autoantibodies in ITP were provided by Christie et al (1993) and van der Harst et al 
(1990). These investigators reported that antibodies in immune thrombocytopenias 
were light chain restricted and that expanded clonal B-cell populations were 
commonly present. 
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Cellular immunity 
Abnormal production of autoantibodies in autoimmune states may be due to intrinsic 
defects within the B-lymphocyte populations or due to aberrant mechanisms which 
indirectly influence the B-cells. Abnormalities in cellular immunity have previously 
been reported in a number of autoimmune diseases, and multiple lymphocyte defects 
are known to be present in chronic ITP (Hymes & Karpatkin, 1990; Semple & 
Freedman, 1992). Most studies have been performed on T-cell abnormalities and 
contradicting results have often been obtained; several investigators have reported a 
decrease in CD8+ T-suppressor lymphocytes and changes in the CD4+/CD8+ ratios 
(Trent et al, 1981; Lauria et al, 1981; Peller et al, 1986;), whereas others have 
reported normal CD4+/CD8+ ratios and increases in CD4+ and CD8+ T-lymphocytes 
(Lauria et al, 1983; Scott et al, 1983; Mizutani et al, 1985; Semple & Freedman, 1991). 
Mizutani et al (1991) reported an increase in circulating and splenic CD5+ B-
lymphocytes in patients with ITP, and Semple & Freedman (1991) found an increase 
in CD 19+ B-cells, among which CD5+ B-cells are a subset. A T-suppressor cell (CD8+) 
hyporesponsiveness, with concomitant increase in autoreactive T-helper cells (Hymes 
& Karpatkin, 1990; Semple & Freedman, 1991), may be responsible for an 
inappropriate autoantibody production. Based on flow cytometric analysis, two 
independent groups of investigators have also demonstrated expanded clonal B-cell 
populations in immune thrombocytopenias (van der Harst et al, 1990; Christie et al, 
1993). However, these clonal expansions were not restricted to CD5+ B-cells. 
Blood group ABH antigens 
ABH antigens are carbohydrates being attached to oligosaccharide core moieties on 
glycolipids and glycoproteins (Watkins, 1980). Also, it is well recognized that human 
platelets carry blood group ABH antigens both as extrinsic antigens passively 
adsorbed from plasma and as intrinsic antigens (Dunstan et al, 1985; Dunstan & 
Mansbach, 1985). Impaired platelet recovery remains to be a problem in the 
transfusion of ABO-incompatible platelets (Aster, 1965; Duquesnoy et al, 1979; Brand 
et al, 1986; Heal et al, 1987; Ogasawara et al, 1993). The ABH-expressing 
glycoproteins carry glycan in two different ways; glycosylation may occur at 
asparagine sites by linking D-ß-N-acetylglucosamine to the amino group (AT-glycan), 
or at serine or threonine sites by linking D-a-acetylgalactosamine through the 
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hydroxyl group (O-glycan) (Clausen & Hakomori, 1989). The protein based expression 
of blood group ABH determinants on platelets has been assigned to the GPs lb, IIa, 
IIb, Ilia, and PECAM (Santoso et al, 1991; Ogasawara et al, 1993; Santoso et al, 1993; 
Hou et al, 1996). Most recently, it was reported by our group that ABH antigens were 
expressed on some other uncharacterized glycoproteins, having a molecular weight of 
70-90 kD; with respect to the molecular weight we considered GPIV and GPV as likely 
candidates (Hou et al, 1996). Indeed, GPIV and GPV are major platelet membrane 
GPs, with approximately 20,000 and 11,000 copies, respectively, on a resting platelet 
(Legrand et al, 1991; Modderman et al, 1992). The numbers of the potential 
glycosylation sites of GPIV and GPV have been elucidated by the complete cDNA-
deduced protein sequences and by compositional analysis of the purified glycoproteins 
(Oquendo et al, 1989; Lanza et al, 1993); GPIV and GPV were found to have as many 
as ten and eight potential AT-glycosylation sites, respectively. Hence, it is theoretically 
suggestive that these two glycoproteins should contain ABH blood group 
determinants. 
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AIMS OF THE INVESTIGATION 
The objectives of the present study were: 
to evaluate different techniques suitable for large scale screening of serum platelet 
antibodies 
to explore the hypothesis of oligoclonaiyclonal autoantibodies in chronic ITP 
to examine the homogeneity of autoantigen epitopes on GPIIb/IIIa in chronic ITP 
to further characterize the 70-90 kD, blood group A antigen expressing platelet 
membrane glycoproteins 
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MATERIAL AND METHODS 
I. Patients and controls 
Sera from patients with chronic ITP were the core of the study. The diagnosis of 
chronic ITP was based on the following findings: a thrombocytopenia persisting for 
more than 6 months, normal or increased numbers of megakaryocytes in a bone 
marrow biopsy, normal spleen size, and no other known causes of the 
thrombocytopenia. Further clinical characteristics for the patients are given in the 
respective papers. 
Sera from healthy blood donors with no history of blood transfusions or pregnancy 
served as negative controls. 
An anti-HPA-la (anti-PlA1) serum was obtained from a HPA-la-negative (P1A1-
negative) woman who had been treated with buffy coat transfusions because of 
repeated miscarriages; at two subsequent pregnancies she gave birth to babies with 
neonatal alloimmune thrombocytopenia. 
All sera were stored at -70° C until used in the assays 
II. Platelets 
Platelets from healthy blood group O donors were isolated from EDTA-anticoagulated 
whole blood by differential centrifugation and washed twice with 0.01 M phosphate 
buffered sahne (PBS), pH 7.4, containing 10 mM EDTA. The platelet counts were 
determined using an automatic cell analyzer ( H2, Technicon, USA). 
III. Platelet lysate 
Washed platelets (1 x 108) were resuspended in 90 pi 50 mM Tris, 145 mM NaCl 
buffer (TBS), pH 7.5, mixed with 10 pi 10% Triton X-100, and agitated for 30 minutes 
at 4° C. The solubilized platelets were then centrifuged for 30 minutes at 26,000 g to 
pellet the insoluble material. The supernatant platelet lysate was stored frozen at -70° 
C until used as a source of soluble platelet proteins. 
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IV. Biotinylation of platelet membrane proteins (paper V) 
Instead of the commonly used radiolabelling techniques, we employed a non­
radioactive method for cell surface labelling. This technique has previously been 
described by other investigators (Fabris et al, 1992; Smith et al, 1993). Briefly, washed 
platelets, at a concentration of 1 x 109/ml, were incubated with 5 mM NHS-LC-Biotin 
(Pierce, USA), in 0.01 M PBS/EDTA, pH 7.4, for 30 min at ambient temperature. The 
platelets were then washed three times with PBS/EDTA and resuspended in the same 
buffer. 
V. Purification of IgG and IgG-F(ab')2 fragments (paper IV) 
IgG was purified from 1 ml aliquotes of patients and normal sera by affinity 
chromatography on a protein A-sepharose column. Following elution from the column 
IgG was extensively dialyzed with 0.01 M PBS, pH 7.4. IgG-F(ab')2 fragments were 
prepared from the purified IgG by solid phase pepsin digestion according to the 
manufacturer's instructions (F(ab')j preparation kit, Pierce, USA). Undigested IgG 
and large Fc fragments were absorbed by protein A chromatography, and small Fc 
fragments removed by dialysis. F(ab')2 fragments were verified by molecular weight 
analysis, using sodium dodecyl sulfate - Polyacrylamide gel electrophoresis (SDS-
PAGE) and silver staining, showing a single band at 120 kD. 
VI. IgG-F(ab')2 blocked and unblocked platelets (paper IV) 
These platelets were used to evaluate whether IgG-F(ab')2 fragments from one ITP-
patient were able to inhibit the platelet binding of autoantibodies from other patients 
with chronic ITP. IgG-F(ab')2 fragments were prepared from healthy volunteers, and 
from two prototype ITP patients with an unusually strong, high titer, antibody specific 
for platelet GPIIb/IIIa. Platelets from normal blood group O and HPA-la (P1A1) 
positive donors were isolated, washed, and resuspended to a concentration of 1 x 
109/ml. One ml of the platelet suspension was incubated with 1 mg ITP-prototype or 
normal IgG-F(ab')2 fragments. After washing and resuspension, the IgG-F(ab')2 
blocked and unblocked platelets were used as a source of platelet antigens in the 
MAIPA assay. 
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VII. Lymphocyte preparation (paper III) 
Mononuclear cells were prepared from heparin anticoagulated whole blood. The blood 
was diluted with an equal volume of 0.01 M PBS, pH 7.4, and 4 ml of the blood 
suspension were layered on 3 ml Ficoll-Isopaque (Pharmacia AB, Sweden) and 
centrifuged at 400 g for 30 min. The mononuclear cell fraction was harvested, washed 
twice, and finally resuspended in 0.01 M PBS. 
VIII. DNA-preparation (paper III) 
Genomic DNA was prepared from 5 ml EDTA anticoagulated whole blood using a 
miniscale salting out technique (Miller et al, 1988). The DNA concentration was 
measured at 260 nm using a spectrophotometer, and the samples were stored at -20°C 
until analysis. 
IX. Immunoassays for platelet antibody detection 
IX. 1. Whole platelet ELISA (paper I). Briefly, blood group O platelets from normal 
donors were isolated from ACD-anticoagulated blood, washed with a Ringer-Citrate-
Dextrose buffer, and 1 x 106 platelets were placed into each well of a tissue culture 
treated microtiter plate (Nunclon, NUNC, Denmark). After centrifugation, the plate 
was drained and blotted on absorbent paper. Following an overnight incubation in a 
vacuum dessicator the plates were washed twice and blocked with PBS/0.05%Tween-
20/3%BSA for 90 min. Thereafter, 50 pi serum (diluted 1/10) was added in triplicate 
to the wells and incubated for 60 minutes at room temperature. Following washes, 
alkaline phosphatase conjugated goat anti-human Ig (IgG, A, M) was added and the 
plates were incubated for 45 minutes at room temperature. After four subsequent 
washes, the substrate p-nitrophenyl phosphate (PNPP) was added and the absorbance 
recorded at 405 nm using a microtiter plate reader. Four control sera were studied in 
association with each assay in order to serve as an internal standard. Reactions above 
the mean absorbance + 3SD recorded for these 4 control sera were regarded as 
positive. 
IX.2 Modified antigen capture ELISA (MACE) (paper I). Washed normal 
platelets from blood group O donors were prepared, and 4 x 107 platelets were 
incubated (sensitized) with 100 pi test sera for 60 minutes, washed and solubilized in 
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TBS containing 1% Triton X-100. Insoluble material was removed by centrifugation 
and the supernatant sensitized platelet lysate was added in duplicate to the wells of 
a microtiter plate (Maxisorp, NUNC, Denmark), that had been coated with either 
MoAb API (specific for platelet GPIb) or MoAb AP2 (specific for platelet GPIIb/IIIa). 
The IgG bound to the captured glycoprotein was detected using biotinylated MoAb 
HB43 (specific for the Fc-portion of human IgG) and an avidin-biotin-alkaline 
phosphatase complex (Vectastain ABC-AP kit, Vector Laboratories Inc., USA). PNPP 
was used as substrate and the absorbance was recorded at 405 nm in a microtiter 
plate reader. Four control sera were studied in association with each assay in order 
to serve as an internal standard. Reactions above the mean absorbance + 3SD 
recorded for these 4 control sera were regarded as positive. The MoAbs API and AP2 
were generous gifts from Drs Montgomery and Kunicki, at the Blood Research 
Institute, the Blood Center of SE Wisconsin, Milwaukee, USA. 
IX.3 Flow cytometric detection of platelet antibodies (paper I). Platelet-rich 
plasma (PRP) was prepared from normal blood group O donors and the platelet count 
was adjusted to 500 x 109/1. One hundred pi of the platelet suspension was mixed with 
100 pi of test serum and incubated for 1 hour at room temperature. After two 
subsequent washes the platelet bound immunoglobulins were detected by adding 100 
pi fluorescein (FITC) conjugated goat anti-human immunoglobulin (secondary 
antibody). Three different secondary antibodies specific for human IgG (y-chain), IgA 
(a-chain), and IgM (p-chain) were employed. After 45 minutes incubation the platelets 
were washed twice, resuspended in 0.01 M PBS and immediately analyzed on the flow 
cytometer (FACScan, Becton Dickinson, USA). Four control sera were studied in 
association with each assay in order to serve as an internal standard. A median 
fluorescence intensity (MFI) above the mean MFI + 3SD recorded for these 4 controls 
was considered as positive. 
IX.4 Antigen capture ELISA (paper V). Reactions of human anti-A and anti-A, B 
sera with platelet glycoproteins were studied using an antigen capture ELISA. In this 
assay, the glycoprotein of interest was immobilized by MoAbs attached to the wells 
of a microtiter plate. Briefly, 50 pi of the MoAbs CLB-IVC7 IgG (specific for platelet 
GPIV) or CLB-SW16 IgG (specific for GPV) (Chemicon AB, Sweden) in PBS, at a 
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concentration of 10 pg/ml, were added to each well of a 96-well microtiter plate 
(Maxisorp, NUNC, Denmark), that had been coated with affinity purified goat anti-
mouse IgG, and incubated for 60 minutes at ambient temperature. After washing the 
plate was blocked for 30 minutes. The wells were then incubated with 50 }il dilu ted 
platelet lysate for 60 minutes, for capturing of the respective glycoprotein. Following 
four additional washes 50 jil of hu man anti-A or anti-A, B sera (Immucor Inc., USA) 
were added to the wells, and the plate was incubated for 60 minutes. Thereafter, the 
wells were washed four additional times, alkaline phosphatase conjugated goat anti-
human Ig (IgG, A, and M specific) were added, and the plate incubated for another 
45 minutes. Finally, the plate was washed four times and PNPP as substrate was 
added. The absorbance was recorded at 405 nm. 
DL5. Modified monoclonal antibody specific immobilization of platelet 
antigens (MAIPA) (paper II-IV). Washed platelets from normal blood group O 
donors were prepared. One hundred pi of the platelet suspension (1 x 108 platelets) 
were mixed (sensitized) with 100 pi test serum, incubated and thereafter solubilized 
in TBS containing 1% Triton X-100 and 100 jig/ml leupeptin. Insoluble material was 
removed by centrifugation. A MoAb, specific for the glycoprotein of interest, i.e. 
GPIb/IX and GPIIb/IIIa, was added to each well of a microtiter plate (Maxisorp, 
NUNC, Denmark) that had been coated with affinity purified goat anti-mouse IgG by 
overnight incubation. After washing the plate, 100 pi of "sensitized" platelet lysate 
were added to the wells in duplicate. After incubation and washes, 100 pi of ei ther 
alkaline phosphatase conjugated goat anti-human IgG, goat anti-human kappa or goat 
anti-human lambda were added and the plate incubated. Finally, the plate was 
washed and PNPP as substrate was added. The absorbance was recorded at 405 nm 
using a microtiter plate reader. Four control sera were studied in association with 
each assay in order to serve as an internal standard. An absorbance greater than 
twice the mean absorbance recorded for the controls, or above control mean + 3SD 
was considered as a positive reaction. 
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X. Clonal excess analysis 
X.1. Flow cytometric clonal excess analysis. Mononuclear cells were prepared 
from heparin anticoagulated blood by using a Ficoll-Isopaque gradient. One hundred 
pi of the mononuclear cell suspension, approximately 1 x 106 leukocytes, were mixed 
with rabbit serum to block non-specific b inding sites. After washing the cells were 
divided into aliquotes and incubated with fluorochrome conjugated MoAbs or affinity 
purified polyclonal antisera (for details see paper IV); appropriate antisera were used 
for identification of T- (CD3+) and B-lymphocytes (CD 19+), and for kappa- and 
lambda-immunophenotyping of CD19+ B-cells. After incubation the cells were washed 
twice, resuspended in 0.01 M PBS containing 1 % paraformaldehyde, and then 
analyzed on a flow cytometer (FACScan, Becton Dickinson, USA). The lymphocyte 
population was identified and a lymphocyte gate was set. The fluorescence of CD3-
fluorescein (FITC) and CD19-phycoerytrin (PE) was analyzed to enumerate the 
number of T- and B-lymphocytes. A threshold was set at the nadir between CD19- and 
CD 19+ cells in the kappa/lambda/control vs CD 19 analysis, and a combined gate in 
FSC-SSC dot plot and F12 was constructed to include only CD 19+ lymphocytes. The 
proportion of k appa- and lambda-expressing CD 19+ lymphocytes was determined 
within this gate. A clonal excess of B-cells was considered to exist if either a discrete 
population with intermediate antigen expression was seen, or if a kappa/lambda ratio 
>3 or <0.5 was observed. Two patients with chronic lymphocytic leukemia, one having 
a kappa phenotype and the other a lambda phenotype, served as positive controls. 
X.2. Polymerase chain reaction (PCR) amplification of the hypervariable 
complementarity determining region 3 (CDR3) of the heavy chain Ig-gene 
(paper III). This technique has previously been described by Brisco et al (1990). 
Briefly, consensus primers, flanking the hypervariable CDR3 region of t he heavy 
chain Ig-gene, were employed, and the region of interest was amplified using a 
standard PCR-protocol with a "hot start" technique (for d etails see paper IV). The 
PCR products were separated on a 4.4 % NuSieve®/Agarose gel and visualized in UV-
light after staining with ethidium bromide. DNA from healthy volunteers served as 
a negative control, and DNA from a patient with chronic lymphocytic leukemia, 
serially diluted in normal DNA, was used as a positive control. 
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XI. Iramunoprecipitation (paper V) 
One hundred aliquotes of biotinylated or unlabelled platelet suspensions, at a 
concentration of 1 x 109/ml, were each incubated with the MoAbs CLB-IVC7 (anti-
GPIV) or CLB-SW16 (anti-GPV) for 60 minutes. The antibody-sensitized platelets 
were then washed four times with PBS/EDTA, and solubilized in 100 pi TBS, pH 8.5, 
containing 1% Triton X-100, leupeptin, and phenylmethylsulfonyl fluoride (PMSF). 
The insoluble material was removed by centrifugation, and 20 pi of a 1:1 slurry of 
Protein A-Sepharose CL-4B (Pharmacia AB, Sweden) were added to the supernatant, 
and the mixture was incubated for 3 hours at 4° C. The Protein A beads were pelleted 
and washed four times. Bound proteins were eluted by resuspending the final bead 
pellet in 70 pi of SDS-PAGE sample buffer and incubating the mixture at 100° C for 
5 minutes. The mixture was then centrifuged at 12,000 g for 1 min. The supernatants 
were electrophoresed on a 5 to 15% gradient SDS-PAGE gel under nonreduced and 
reduced conditions using the discontinuous buffer system of Laemmli (1970). Broad 
range biotinylated weight standards (Bio-Rad Lab., USA) were included to allow 
localization of the major labeled platelet proteins. After completion of the run the gel 
was equilibrated in Towbin buffer (Towbin et al, 1979) for 15 minutes, and then 
electrotransferred to a 0.45 pm pore-size nitrocellulose membrane (Bio-Rad Lab., 
USA) using the same buffer. The membrane was then blocked with TBS-0.05%Tween-
3%BSA. After two subsequent washes the lanes of the membrane holding 
immunoprecipitated biotinylated platelet GPs were cut out and incubated with an 
avidin-biotin-alkaline phosphatase complex diluted 1:500 in TBS-Tween-BSA. After 
an additional four washes in TBS-Tween the bands were developed with the 
NBT/BCIP substrate. The remaining lanes of the membrane, holding 
immunoprecipitated unlabeled platelet GPs were used for immunoblotting. 
XII. Immunoblotting of the immunoprecipitated platelet GPs (paper V) 
The membrane lanes holding immunoprecipitated and unlabeled platelet GPs were 
incubated with the MoAb 402-3D9 (specific for blood group A antigen) (New Monocarb, 
Sweden) for 2 hours at 4° C. The membrane was then washed and incubated with 
biotinylated goat anti-mouse IgG for 60 minutes. After additional washings the bands 
were developed using the ABC-AP kit and NBT/BCIP as substrate, as described 
above. 
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RESULTS AND DISCUSSION 
Comparison of three methods for detection of platelet antibodies in 
patients with chronic ITP (paper I) 
Sera from an unselected group of patients with chronic ITP were used for this study, 
and the purpose was to compare different techniques suitable for large scale screening 
of serum platelet antibodies. Two of these methods used whole platelets as targets for 
the antibodies (flow cytometry and whole platelet ELISA), and the third assay was an 
antigen-specific ELISA (MACE), in which GPIb/IX and GPIIb/IIIa were captured with 
monoclonal antibodies. The whole platelet based assays will irrespective of their 
specificity detect all immunoglobulins attached to the platelet surface. Thus, these 
techniques cannot discriminate between platelet autoantibodies bound to membrane 
GPs, alloantibodies bound to HLA-antigens, and immune-complexes bound to the 
platelet FcyRII-receptors. 
We detected platelet antibodies in 35% of the ITP-sera using the whole platelet 
ELISA, and in about 45% of the sera with the flow cytometric technique. This 
frequency of se rum platelet antibodies in ITP is in accordance with the reports of 
other investigators, in which similar techniques were employed, i.e. the platelet 
membrane ELISA (Winiarski & Ekelund, 1986) and the platelet suspension 
immunofluorescence test (PSIFT) (von dem Borne et al, 1980). The present 
immunoglobulin class analysis of platelet antibodies demonstrated that IgG was the 
most frequent antiplatelet immunoglobulin (26/29 patients); however, IgG was 
sometimes detected together with IgA and/or IgM. Only three sera displayed platelet 
antibodies only belonging to the IgA and/or IgM class, a finding in accordance with 
the results of von dem Borne et al (1980). 
By employing an ELISA (MACE), which detected antibodies binding to platelet 
GPIb/IX and GPIIb/IIIa, we found that 23 out of 65 ITP sera (35%) possessed 
antibodies with these specificities; antibodies against GPIb/IX were most frequently 
observed, either alone or in combination with anti-GPIIb/IIIa. Of the patients positive 
in the MACE-assay only 61% gave positive results in the whole platelet ELISA and 
78% in the flow cytometric assay. In previous reports the finding of autoantibodies 
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against GPIb/IX has been considered uncommon (Woods et al, 1984a; Szatkowski et 
al, 1986; McMillan et al, 1987). However, by employing the MAIPA-assay, a technique 
similar to the antigen-specific assay used by us, Kiefel et al (1991) found that 
antibodies against GPIb/IX were as common as antibodies against GPIIb/IIIa. None 
of the assays employed in the present study had a sensitivity high enough to be 
recommended for routine diagnostic use in chronic ITP. However, in certain cases of 
ITP and for thorough evaluation of the autoimmune process in ITP, it seems 
reasonable to use a whole platelet based assay in conjunction with an antigen specific 
assay; the whole platelet based assay might detect uncommon antibody targets, and 
the specificity of the antibodies can be confirmed with the antigen specific ELISA by 
using appropriate capturing Mo Ab. 
Light chain restricted autoantibodies in chronic ITP (paper II) 
Assuming that the autoantibody production in chronic ITP is due to an expansion of 
one or a few autoreactive B-cell clones, and if the autoantigen repertoire on platelet 
glycoproteins is limited, the antibodies should possess monoclonal characteristics, e.g. 
a restriction as to their light chain phenotype and subclass. Indeed, in the present 
study we found that the GPIb/IX and GPIIb/IIIa specific antibodies in ITP frequently 
were restricted to either kappa or lambda light chains, supporting the hypothesis of 
clonally derived autoantibodies in ITP. 
Several additional lines of evidence support the hypothesis of a limited autoantigen 
repertoire in chronic ITP: first, certain GP-specific murine monoclonal antibodies 
compete with the ITP autoantibodies in their binding to the glycoprotein (Varon & 
Karpatkin, 1983); second, human monoclonal autoantibodies generated from a patient 
with ITP behaved as if they were selected by an antigen-driven clonal maturation 
(Nugent et al, 1989; Hiraiwa et al, 1990); and third, proteolytic fragments of GPIIIa 
are frequent targets for autoantibodies in ITP (Kekomaki et al, 1991). 
Further support for the hypothesis of clonal autoantibodies in chronic ITP has been 
obtained by two independent investigators; on a rather crude patient material with 
immune thrombocytopenias they found light chain restricted platelet antibodies, and 
expanded clonal B-cell populations were commonly present (van der Harst et al, 1990; 
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Christie et al, 1993). In the present study we employed sera from 19 patients with 
an unequivocal diagnosis of chronic ITP and secondary causes, e.g. 
lymphoproliferative disorders, were specifically ruled out. All of our ITP patients were 
also known to have serum antibodies binding to GPIIb/IIIa and/or GPIb/IX. Thus, the 
novel finding of the present work was that chronic ITP patients without any 
secondary cause displayed light chain restricted platelet antibodies in a high 
frequency. 
Light chain restricted autoantibodies but no circulating clonal B-
lymphocytes (paper III) 
The homogeneity of Ig-proteins can be used as a clonality marker in B-cell disorders, 
e.g. the presence of a monoclonal gammopathy, a disproportional number of B-cells 
having either a kappa (K) or lambda (X.) ligh t chain immunophenotype, and clonal 
rearrangements of hypervariable Ig-gene regions. The flow cytometric clonal excess 
analysis is based on the fact that the normal ratio of K- and ^-expressing B-
lymphocytes is approximately 3:2 (Johnson & Olofsson, 1993). Thus, if all B-cells in 
a lesion express either the K or the X imm unophenotype, it is very likely that the 
les ion  i s  a  c lonal ly  d e r ived  t umor .  On  the  o ther  ha nd ,  i f  the  ra t io  o f  K -  and  X -
expressing B-cells is fairly normal it is suggestive that the lesion is a polyclonal or 
non-neoplastic proliferation (Abbas, 1994). 
Furthermore, it is now well established that rearrangements of separate Ig gene 
segments provide the diversity for antigen recognition by B-cells. These events can 
provide useful markers of clonality, cellular origin, and stage of B-cell differentiation 
in the study and diagnosis of B-cell disorders. In particular, the diversification of 
heavy chain genes is generated by recombination of variable (VH), diversity (D) and 
joining (JH) gene segments. Additional variability in the heavy chain gene sequence 
is introduced by random deletions and insertions of nucleotides at the V-D and D-J 
junctions, as well as somatic mutations (Tonegawa, 1983). The junctional sequences 
correspond to the complementarity determining region 3 (CDR3) of the heavy chain 
gene and are quite specific to individual alleles. Recently, a number of laboratories 
have described application of polymerase chain reaction (PCR) techniques to 
significantly increase the sensitivity and specificity of clonal B-cell detection (Brisco 
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et al, 1990; Trainor et al, 1990; Billadeau et al, 1991). Using primers homologous to 
consensus sequences in the VH and JH gene segments, the CDR3 region can be 
amplified, sequenced, and subsequently used as a probe to detect residual malignant 
B-cells clones from as few as 1 in a background of 105 cells (Trainor et al, 1990). 
In the present study (paper III) we were able to reconfirm our previous finding (paper 
II) of light chain restricted platelet antibodies in chronic ITP, by analyzing the 
platelet antibody K/X-phenotype in 20 new patients. However, in these patients we 
could not detect any clonally expanded B-cell population, by employing a flow 
cytometric "clonal excess" analysis or by PCR rearrangement studies of the heavy 
chain Ig-gene. These latter results are consequently at variance with the reports by 
van den Harst et al (1990) and Christie et al (1993). Indeed, there are several possible 
explanations for the contradictory findings. First, van der Harst et al (1990) studied 
11 patients with ITP, 4 of whom even displayed paraproteinemia and only four were 
diagnosed as chronic ITP. Further, no data characterizing platelet reactive antibodies 
were presented in their report. Also, the study by Christie et al ( 1993) was performed 
on a crude patient material with immune thrombocytopenias and miscellaneous 
malignant hematological disorders, holding only two patients with chronic ITP; the 
majority of the molecular studies were performed on blood samples obtained up to 24 
months after the serological studies, and a discrepancy was found between the light 
chain phenotypes of the platelet reactive antibodies and the clonal B-cells. Indeed, 
different mechanisms might account for the presence of clonal B-cells in patients with 
thrombocytopenia due to autoimmunity, alloimmunity, and drug-induced-immunity, 
respectively. The chronic ITP patients exploited in our study were not confounded by 
other disorders which might affect the results obtained from clonality analysis. Thus, 
patients afflicted with secondary immune thrombocytopenias and particularly 
paraproteinemias were excluded from the present study. Second, the flow cytometric 
clonal excess assay and Ig-gene rearrangement analysis by PCR, at their best have 
detection limits of approximately 10% and 1%, respectively (Trainor et al, 1990; 
Agrawal et al, 1992; Johnson & Olofsson, 1993). Hence, clonally expanded B-cell 
populations, if they really exist in chronic ITP, are most probably below the detection 
limits of the assays employed. 
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Glycoprotein Ilb/IIIa autoantigenic repertoire in ITP (paper IV) 
The objective of this paper was to further disclose the autoantigenic repertoire carried 
by the GPIIb/IIIa complex. IgG-F(ab')2 fragments prepared from two prototype ITP 
sera, known to possess a high titer GPIIb/IIIa specific antibody, were each able to 
block the binding of serum GPIIb/IIIa-specific antibodies in 6 (55%) and 7 (64%) out 
of 11 patients with chronic ITP, respectively. The blocking of serum IgG binding to 
GPIIb/IIIa could be due to the fact that prototype IgG-Ftab'^ fragments preoccupied 
the homogenous autoepitopes. Another explanation could be that autoantigenic 
determinants on GPIIb/IIIa were perturbed by the binding of p rototype IgG-F(ab')2 
fragments to a very close determinant. Conversely, failure in blocking the binding of 
serum IgG to GPIIb/IIIa can be a consequence of: first, that the prototype IgG-F(ab')2 
fragments and autoantibodies bind to heterogenous epitopes on GPIIb/IIIa; second, 
that in extremely rare circumstances, the GPIIb/IIIa reactive antibodies in ITP sera 
could be platelet specific alloantibodies beyond the HPA-1 (piAiyA2) system. 
Furthermore, our data are in accordance with the concept of a homogenous 
autoantibody repertoire, specific for GPIIb/IIIa, in a significant fraction of chronic ITP 
patients (Varon & Karpatkin, 1983; Fujisawa et al, 1990; Kekomaki et al, 1991). By 
analyzing the competitive binding between human autoantibodies and murine MoAb 
specific for GPIIb/IIIa Fujisawa et al (1990) observed a decreased amount of platelet-
bound anti-GPIIb/IIIa MoAb in 5 out of 22 (23%) patients with chronic ITP, indicating 
binding of autoantibodies directed toward antigenic determinants on or close to the 
epitope of the MoAb. Using enzyme cleaved GPIIIa fragments, Kekomaki et al (1991) 
found that a 33 kD chymotryptic core fragment of GPIIIa was bound by 48% (15/31) 
of patients with chronic ITP. Furthermore, employing the hydrophatic 
complementarity approach, De Souza et al (1992) reported that 5 out of 17 (30%) 
GPIIb/IIIa reactive ITP sera also bound to a peptide deduced from the complementary 
nucleotide sequence to that which codes for the Arg - Gly - Asp (RGD) domain in 
fibronectin. Recently, Fujisawa et al (1992) showed that 13 out of 21 (62%) GPIIb/IIIa 
reactive sera bound primarily to the carboxy terminus of GPIIIa. 
In summary, we have provided evidence that as defined by serum autoantibodies, half 
of the ITP patients with GPIIb/IIIa reactivity seem to share a homogenous GPIIb/IIIa 
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autoantigenic repertoire. Considering that light chain restricted antibodies and 
circulating clonal B-cells have been shown to exist in chronic ITP (van der Harst et 
al, 1990; Christie et al, 1993), the total number of autoantigenic epitopes on 
GPIIb/IIIa ought to be quite limited. 
Evidence for an expression of blood group A antigen on platelet GPIV 
and GPV (paper V) 
The expression of blood group ABH determinants on platelet has been assigned to 
glycolipids and to glycoproteins lb, IIa, IIb, Ilia, and PECAM (Santoso et al, 1991; 
Santoso et al, 1993; Ogasawara et al, 1993; Hou et al, 1996). Most recently we 
observed that a MoAb specific for blood group A antigen immunoblotted some other 
proteins derived from SDS-PAGE separated blood g roup A1 platelet lysates (Hou et 
al, 1996). These ABO-expressing platelet proteins had molecular weights ranging 
between 70-90 kD, and their electrophoretic mobility was unaffected by 2-
mercaptoethanol reduction (Hou et al, 1996). Considering the molecular weight and 
the number of potential glycosylation sites on platelet GPIV and GPV (Oquendo et al, 
1989; Legrand et al, 1991; Modderman et al, 1992; Lanza et al, 1993), we found it 
theoretically suggestive that these two glycoproteins should contain ABH blood group 
determinants, and could account for the 70-90 kD uncharacterized bands seen in the 
anti-A immunoblot. 
The following lines of evidence were obtained by us, regarding the characterization 
of the 70-90kD platelet proteins holding the blood group A antigen. First, by antigen 
capture ELISA, wherein the MoAbs CLB-IVC7 (specific for GPIV) and CLB-SW16 
(specific for GPV) were used to hold the corresponding antigens, human anti-A 
specifically bound to these proteins derived from Arplatelets. Neither GPIV nor GPV 
derived from Aj-, B-, or O-platelets bound anti-A. In the same assay, human anti-A, 
B bound to both GPIV and GPV derived from A, as well as B-platelets. This latter 
finding suggests that blood group B-antigen is also expressed on GPIV and GPV 
derived from blood group B platelets. Second, in a Western blot assay using 
immunoprecipitated GPIV and GPV as antigens, MoAb anti-A immunostained GPIV 
and GPV precipitated from Au but not from A2 and O platelets. These results 
demonstrate that blood group A antigen is expressed on platelet GPIV and GPV. 
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It is noteworthy that binding of human polyclonal anti-A in the ELISA assay and that 
of murine MoAb anti-A in the immunoblot assay, were only detected by platelets from 
blood group A, individuals, whereas A, platelets did not display any significant 
reactivity. Similar findings have been observed in the study of other ABO-expressing 
platelet glycoproteins (Holgersson et al, 1990; Santoso et al, 1991; Hou et al, 1996). 
The present observations provide additional biochemical basis for the clinirnl 
refractoriness in the transfusion of ABO-incompatible platelets, (Aster, 1965, 
Duquesnoy et al, 1979; Brand et al, 1986; Heal et al, 1987; Ogasawara et al, 1993). 
Also, a platelet A/Aj difference was evidenced, which might explain why blood group 
Aj platelets serologically behave as blood group O platelets in clinical platelet 
transfusions (Skogen et al, 1988). 
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CONCLUSIONS 
I. Whole platelet based techniques and antigen specific techniques used for platelet 
antibody detection have their merits and demerits; it appears reasonable that they 
should be used together in evaluation of the autoimmune process of chronic ITP. 
II. At least half of the ITP patients with GPIIb/IIIa reactivity seem to share a 
homogenous autoantigenic repertoire. Considering the evidences for clonal 
autoantibodies in ITP, it is justifiable to assume that the number of au toantigenic 
epitopes on platelet GPIIb/IIIa is quite limited. If this hypothesis holds true, novel 
diagnostic and treatment strategies can be opened, e.g. anti-idiotypic therapies and 
specific immunabsorption. 
III. Blood group A-antigen is expressed on platelet GPIV and GPV derived from blood 
group Aj but not A2 platelet. Hereby, additional biochemical basis for the clinical 
refractoriness in the transfusion of ABO-incompatible platelets is provided. Also, this 
finding emphasizes that even in glycoprotein specific immunoassays should proteins 
from blood group O platelets be used as the antibody target, in order to avoid 
interference from ABO-antibodies. 
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